Skip to content
    Reviews

    PFS as a Surrogate Endpoint for OS in Oligometastatic Cancer Trials

    Chen et alThe oncologist

    PFS as a Surrogate Endpoint for OS in Oligometastatic Cancer Trials
    A systematic review and surrogacy meta-analysis evaluated the standardization of clinical trial endpoints and the surrogacy relationship between progression-free survival (PFS) and overall survival (OS) in prospective studies of metastasis-directed therapy (MDT) for oligometastatic cancer. Searching major databases (Ovid MEDLINE, Embase, CENTRAL, and ClinicalTrials.gov) through June 2025, investigators identified 235 prospective studies, encompassing 29 randomized trials (86% of which were phase II), 35 non-randomized studies, and 171 clinical trial registrations.
    Endpoint distribution among randomized trials revealed a strong reliance on progression-based measures: PFS was the primary endpoint in 67% of trials (n = 20), while OS served as the primary endpoint in only 13% (n = 4). In a trial-level surrogacy meta-analysis restricted to the 18 randomized controlled trials reporting both PFS and OS hazard ratios, the endpoints exhibited a moderate correlation (r = 0.80, 95% CI 0.64–0.91). The calculated surrogate threshold effect (STE) was a hazard ratio of 0.79 (95% CI 0.71–0.87), indicating the magnitude of treatment effect on PFS required to reliably predict a statistically significant OS benefit.
    Because the majority of MDT investigations to date are phase II trials where OS is generally not feasible as a standalone endpoint, the authors recommend adopting phase-appropriate endpoint selection. Early- and intermediate-phase trials should pair standardized PFS and local control with patient-centered outcomes such as systemic-therapy-free survival and health-related quality of life, reserving OS or formally validated surrogates for definitive later-phase studies.

    Key Takeaways

    • Across randomized trials evaluating metastasis-directed therapy, progression-free survival (PFS) was the primary endpoint in 67% (n = 20), whereas overall survival (OS) served as the primary endpoint in only 13% (n = 4).
    • Trial-level surrogacy analysis across 18 randomized trials demonstrated a moderate correlation between PFS and OS hazard ratios (r = 0.80, 95% CI 0.64–0.91), with a surrogate threshold effect hazard ratio of 0.79 (95% CI 0.71–0.87).
    • The study findings support implementing phase-appropriate endpoint strategies that combine standardized PFS and local control with patient-centered measures such as quality of life and systemic-therapy-free survival, reserving OS or validated surrogates for later-phase trials.